Stephan Stilgenbauer
YOU?
Author Swipe
View article: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial
Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial Open
Introduction Current treatment for chronic lymphocytic leukemia (CLL) follows two seminal paradigms: continuous Bruton tyrosine kinase inhibitor (BTKi) therapy until progression and fixed-duration regimens combining BCL2 inhibitors with a …
View article: Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study
Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study Open
Introduction: There is no standard of care treatment for Richter transformation (RT) of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) to diffuse large B-cell lymphoma (DLBCL). Existing therapies, including chemoimmunoth…
View article: MRD-guided venetoclax-obinutuzumab in CLL: Final analysis of the CLL2-bag trial of the gcllsg
MRD-guided venetoclax-obinutuzumab in CLL: Final analysis of the CLL2-bag trial of the gcllsg Open
Background: The CLL2-BAG phase 2 trial was among the first to evaluate venetoclax (Ven) plus obinutuzumab (Obi). Another novelty in this trial was the individualized treatment duration based on measurable residual disease (MRD) in peripher…
View article: Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study
Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study Open
Introduction: BGB-16673 is an orally available protein degrader that blocks BTK signaling by tagging BTK for degradation through the cell's proteasome pathway, leading to tumor regression. CaDAnCe-101 (BGB-16673-101; NCT05006716) is an ong…
View article: Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project
Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project Open
Introduction The TRIANGLE trial (Dreyling et al, Lancet 2024) compared three treatment arms in untreated, younger patients with mantle cell lymphoma (MCL): arm I (IR-CHOP/R-DHAP + ibrutinib maintenance [Im]), arm A+I (IR-CHOP/R-DHAP + ASCT…
View article: Peptide-based antagonists for targeting CXCR4 in ibrutinib resistant chronic lymphocytic leukemia
Peptide-based antagonists for targeting CXCR4 in ibrutinib resistant chronic lymphocytic leukemia Open
Bruton tyrosine kinase inhibitors (BTKi) have revolutionized chronic lymphocytic leukemia (CLL) treatment. However, resistance develops, making it important to identify alternative treatment targets. CXCR4, a G protein coupled receptor, re…
View article: CLL to Richter syndrome: Integrating network strategies with experiments elucidating disease drivers and personalized therapies
CLL to Richter syndrome: Integrating network strategies with experiments elucidating disease drivers and personalized therapies Open
Chronic lymphocytic leukemia (CLL) is a common neoplasm that carries the risk of transformation into Richter’s syndrome (RS), a highly aggressive B cell lymphoma with poor prognosis. Limited availability of animal models and cell lines hin…
View article: The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL Open
Venetoclax-obinutuzumab (Ven-Obi) is a standard first-line therapy for chronic lymphocytic leukemia (CLL). The impact of age, fitness, and dose reductions remains unclear. We analyzed patients treated with Ven-Obi in the CLL13 and CLL14 tr…
View article: A noncoding mutation in the <i>NOTCH1</i> gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL
A noncoding mutation in the <i>NOTCH1</i> gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL Open
Chronic lymphocytic leukemia (CLL) is the most common chronic blood cancer in adults. Active NOTCH signaling in CLL is associated with poorer prognosis. Importantly, patients with CLL with NOTCH1 noncoding mutations in the 3′ untranslated …
View article: Genotyping from targeted NGS data based on a small set of SNPs correctly matches patient samples
Genotyping from targeted NGS data based on a small set of SNPs correctly matches patient samples Open
Objective Mislabelling and swapping of laboratory samples are handling errors that can lead to erroneous interpretation of data and/or patient harm. Sequenced samples can be traced back to the respective donors by matching of single nucleo…
View article: NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL Open
Aberrant active NOTCH1 signaling is a key pathogenic factor in chronic lymphocytic leukemia (CLL), detectable in half of patients and associated with disease progression. While some cases of active NOTCH1 signaling can be explained by muta…
View article: Novel ploidy-control genes ORP3 and GJB3 link aneuploidy to tumor cell invasion through microtubule and actin dynamics
Novel ploidy-control genes ORP3 and GJB3 link aneuploidy to tumor cell invasion through microtubule and actin dynamics Open
Aneuploidy is a hallmark of most cancer types, and it is closely related to cancer cell migration and invasion. However, the mechanistic association between aneuploidy and invasive potential of cancer cells is poorly understood. Here, we r…
View article: The significance of <scp>PAX5</scp> in Merkel cell carcinoma
The significance of <span>PAX5</span> in Merkel cell carcinoma Open
Merkel cell carcinoma (MCC) is a highly malignant skin cancer that expresses epithelial‐, neuroendocrine‐, and lymphoid‐associated genes. Here, we focused on B‐cell differentiation, which is characterised by the coexpression of PAX5 and Td…
View article: Future perspectives of fertility protection
Future perspectives of fertility protection Open
Reproductive health is of major importance for individuals, for the society and for the health of future generations. This includes physical and medical dimensions as well as psychosocial and ethical ones. Whenever the possibility of start…
View article: Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL Open
Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder for which primary or acquired drug resistance represents a major challenge. To investigate the underlying molecular mechanisms, we generate a mouse model of ibrutinib…
View article: Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome– paving the path towards precision medicine: a case report
Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome– paving the path towards precision medicine: a case report Open
Background Li-Fraumeni syndrome (LFS) is an autosomal dominant tumor predisposition syndrome characterized by a high familial incidence of various malignancies. It results from pathogenic/likely pathogenic heterozygous constitutional varia…
View article: GPR15LG binds CXCR4 and synergistically modulates CXCL12-induced cell signaling and migration
GPR15LG binds CXCR4 and synergistically modulates CXCL12-induced cell signaling and migration Open
GPR15LG, a chemokine-like ligand for the G-protein coupled receptor 15 (GPR15), is abundantly expressed in the gastrointestinal mucosa and inflamed skin. Emerging evidence suggests its involvement in inflammatory disorders and cancers. Thi…
View article: Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL
Detection of clinically relevant variants in the <i>TP53</i> gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL Open
In chronic lymphocytic leukemia, the reliability of next‐generation sequencing (NGS) to detect TP53 variants ≤10% allelic frequency (low‐VAF) is debated. We tested the ability to detect 23 such variants in 41 different laboratories using t…
View article: Risk-stratification in frontline CLL therapy: standard of care
Risk-stratification in frontline CLL therapy: standard of care Open
The treatment of chronic lymphocytic leukemia (CLL) has been transformed over the past decade based on a better understanding of disease biology, especially regarding molecular genetic drivers and relevant signaling pathways. Agents focusi…